Camrelizumab plus chemotherapy in advanced non‐squamous non‐small cell lung cancer: Treatment response, survival pattern, and safety

培美曲塞 医学 卡铂 化疗 肺癌 内科学 肿瘤科 外科 顺铂
作者
Hui Cao,Wei Wei,Yang Ling
出处
期刊:Journal of Clinical Pharmacy and Therapeutics [Wiley]
卷期号:47 (11): 1775-1782 被引量:2
标识
DOI:10.1111/jcpt.13732
摘要

What is known and objective Camrelizumab, a humanized monoclonal programmed cell death protein-1 antibody independently developed by China, is introduced as a treatment selection for non-small cell lung cancer (NSCLC). This study aimed to evaluate the efficacy and safety of camrelizumab plus chemotherapy in treating advanced non-squamous NSCLC patients. Methods This study retrospectively analysed 31 driver-gene-negative advanced non-squamous NSCLC patients who received a 21-day therapy cycle for four cycles of camrelizumab (intravenous injection, 200 mg/cycle) plus carboplatin and pemetrexed (CP) chemotherapy, followed by maintenance therapy using camrelizumab or pemetrexed or camrelizumab plus pemetrexed. Another 40 patients who underwent CP chemotherapy were retrieved as control group. Results and discussion The objective response rate (ORR) was elevated in camrelizumab plus CP group compared to CP group (58.1% vs. 32.5%, p = 0.031), while disease control rate (DCR) was of no difference between those two groups (83.9% vs. 72.5%, p = 0.255). Camrelizumab plus CP achieved a prolonged PFS compared with CP alone (median: 11.0 (95% CI: 9.1–12.9) months versus 7.2 (95% CI: 5.1–9.3) months, p = 0.026), also realized an increasing OS trend (without statistical significance; 19.3 (95% CI: 15.4–23.2) months versus 15.1 (95% CI: 13.9–16.3) months, p = 0.093). Further multivariate Cox's regression analysis exhibited that camrelizumab plus CP (vs. CP) independently related to prolonged PFS (p < 0.001) and OS (p = 0.027). Moreover, the most common adverse events related to camrelizumab plus CP were fatigue (45.2%), peripheral neuropathy (35.5%), nausea and vomiting (35.5%); furthermore, most adverse events were controllable. What is new and conclusion Camrelizumab plus chemotherapy exhibits good efficacy and manageable adverse events in treating advanced non-squamous NSCLC patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
lulu发布了新的文献求助10
1秒前
1秒前
1秒前
2秒前
柴六斤发布了新的文献求助10
2秒前
无花果的应助被2499297293采纳,获得10
2秒前
3秒前
梅特福斯完成签到,获得积分10
3秒前
3秒前
科目三的应助被活力定帮采纳,获得10
3秒前
Nasser发布了新的文献求助30
4秒前
4秒前
4秒前
sqqx发布了新的文献求助10
4秒前
搜集达人的应助被arT采纳,获得10
4秒前
超帅傲白发布了新的文献求助10
5秒前
小桃完成签到,获得积分10
5秒前
5秒前
ttttt发布了新的文献求助10
5秒前
6秒前
断剑的应助被来一杯忌廉采纳,获得30
6秒前
汉堡包的应助被plj采纳,获得10
6秒前
hah发布了新的文献求助10
6秒前
6秒前
7秒前
乘的号完成签到,获得积分10
7秒前
sonia0720完成签到,获得积分10
8秒前
igor1982发布了新的文献求助10
8秒前
Dugarrygana发布了新的文献求助10
8秒前
科研通AI6.3的应助被大气藏鸟采纳,获得10
8秒前
singefly发布了新的文献求助10
8秒前
hamster完成签到,获得积分10
9秒前
李健的应助被SWZ采纳,获得10
9秒前
文静的摩托完成签到,获得积分10
11秒前
旺财的夏天完成签到,获得积分10
11秒前
12秒前
12秒前
852的应助被外向梦山采纳,获得10
12秒前
Danielle_zx完成签到,获得积分10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175653
求助须知:如何正确求助?哪些是违规求助? 9567273
关于积分的说明 21791766
捐赠科研通 7770183
什么是DOI,文献DOI怎么找? 3431873
关于科研通互助平台的介绍 2556250
邀请新用户注册赠送积分活动 2477299